BA
OMED

BlackRock Advisors’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

BlackRock Advisors’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$103K Buy
13,313
+2,168
+19% +$19.9K ﹤0.01% 3029
2016
Q3 		$127K Sell
11,145
-7,171
-39% -$83.5K ﹤0.01% 2914
2016
Q2 		$225K Buy
18,316
+3,936
+27% +$47.8K ﹤0.01% 2536
2016
Q1 		$146K Buy
14,380
+7,400
+106% +$86.9K ﹤0.01% 2721
2015
Q4 		$157K Sell
6,980
-3,302
-32% -$67.7K ﹤0.01% 2701
2015
Q3 		$171K Buy
10,282
+223
+2% +$4.47K ﹤0.01% 2813
2015
Q2 		$226K Buy
10,059
+3,232
+47% +$79.7K ﹤0.01% 2731
2015
Q1 		$176K Sell
6,827
-18,353
-73% -$466K ﹤0.01% 2752
2014
Q4 		$548K Buy
25,180
+19,924
+379% +$408K ﹤0.01% 1935
2014
Q3 		$99K Sell
5,256
-5,842
-53% -$117K ﹤0.01% 3009
2014
Q2 		$259K Buy
11,098
+7,607
+218% +$188K ﹤0.01% 2474
2014
Q1 		$117K Sell
3,491
-6,462
-65% -$218K ﹤0.01% 2963
2013
Q4 		$294K Buy
9,953
+2,154
+28% +$39.5K ﹤0.01% 2413
2013
Q3 		$119K Buy
+7,799
New +$145K ﹤0.01% 2858

Other funds holding OMED

ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock Advisors's OMED Position: Q4 2016 in Review

BlackRock Advisors increased its OncoMed Pharmaceuticals, Inc. (OMED) stake by 19% in Q4 2016, buying an estimated $19.9K and bringing the position to 13,313 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #3029.

BlackRock Advisors first reported a position in OMED in Q3 2013 and has held it in 14 quarters since. The position peaked at $548K in Q4 2014. 86 funds tracked by Wall St. Rank hold OMED as of Q4 2016.

  • BlackRock Advisors held 13,313 shares of OncoMed Pharmaceuticals, Inc. worth $103K as of Q4 2016.
  • BlackRock Advisors bought 2,168 OncoMed Pharmaceuticals, Inc. shares in Q4 2016, an estimated $19.9K.
  • OncoMed Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3029 holding.
  • BlackRock Advisors first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and has held it in 14 quarters since.
  • BlackRock Advisors's OncoMed Pharmaceuticals, Inc. position peaked at $548K in Q4 2014.
  • 86 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.